Press releases
- Pulse Biosciences Announces Updated Timing of Rights Offering for Up to $60,000,000
- Pulse Biosciences’ CellFX Nanosecond Pulsed Field Ablation (nsPFA™) Technology to be Featured in Several Presentations at The Heart Rhythm Society 2024 Annual Meeting
- Pulse Biosciences Enhances Executive Leadership Team
- Pulse Biosciences Announces First U.S. Procedure with the CellFX nsPFA Percutaneous Electrode System
- Pulse Biosciences Reports Business Updates and First Quarter 2024 Financial Results
- Pulse Biosciences Announces Timing of Rights Offering for Up to $60,000,000
- Pulse Biosciences Schedules First Quarter 2024 Financial Results Conference Call for May 7, 2024
- Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2023 Financial Results
- Pulse Biosciences Announces Plans to Initiate a Rights Offering
- Pulse Biosciences Schedules Fourth Quarter & Full Year 2023 Financial Results Conference Call for March 28, 2024
More ▼
Key statistics
On Friday, Pulse Biosciences Inc (6L8:DUS) closed at 9.50, -22.13% below its 52-week high of 12.20, set on May 29, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 11.00 |
---|---|
High | 11.00 |
Low | 9.35 |
Bid | 10.30 |
Offer | 10.80 |
Previous close | 10.80 |
Average volume | 1.50 |
---|---|
Shares outstanding | 55.23m |
Free float | 16.35m |
P/E (TTM) | -- |
Market cap | 637.85m USD |
EPS (TTM) | -0.8152 USD |
Data delayed at least 15 minutes, as of May 31 2024 18:32 BST.
More ▼